Bold Moves

Transform our go-to-market model

Lead the conversation

Working with policymakers across Europe to ensure the free flow of critical health care materials

At the height of the first wave of the COVID-19 pandemic in Europe, there was unprecedented demand (more than 200%) for Pfizer Hospital/Anti-Infective sterile injectable medicines. While Pfizer leveraged one of the most sophisticated and resilient global supply chain systems in the industry to deliver beyond expectations, governments began implementing measures to ensure patients would have continued access to these critical treatments in their countries. These included proposals around export restrictions, weakening intellectual property rights, mandating stockpiles and other restrictive policies, which Pfizer knew would only have the reverse effect of tightening domestic supply chains.

80 ​​​​​​​million 

Our network of manufacturing sites delivered meaningful quantities of products to meet patient needs. We shipped 17 critical medicines at over 150% of the forecast across Europe. In total, we added approximately 80 million units of sterile injectable medicines to support the demand.

Working across the industry and the health care sector, Pfizer elevated these issues to the highest levels of government. Acting as a leading voice in the collaboration between manufacturers, the European Commission, the European Medicines Agency and Ministers of Health, Pfizer helped solve immediate challenges to the free flow of medicines across Europe. Pfizer also successfully engaged with the European Federation of Pharmaceutical Industries and Associations and Medicines for Europe to secure a competition waiver allowing pharmaceutical companies to work more closely in ensuring steady supply levels of medicines used to support COVID-19 treatments.

We operate one of the most sophisticated supply chain systems in the industry, with more than 40 Pfizer-owned sites and 200 suppliers globally."

At an individual company level, Pfizer established a pandemic preparedness program enabling joint advance supply planning for governments readying for potential future waves of COVID-19.

Pfizer welcomes opportunities to proactively collaborate to take on challenges and meet needs. We are proud to work with governments, hospitals and other health care institutions to provide patients with continued access to Pfizer medicines when they need them most.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories